E-mail a Wiley Online Library Link

Anouk Emadali, Sophie Rousseaux, Juliana Bruder-Costa, Claire Rome, Samuel Duley, Sieme Hamaidia, Patricia Betton, Alexandra Debernardi, Dominique Leroux, Benoit Bernay, Sylvie Kieffer-Jaquinod, Florence Combes, Elena Ferri, Charles E. McKenna, Carlo Petosa, Christophe Bruley, Jérôme Garin, Myriam Ferro, Rémy Gressin, Mary B. Callanan and Saadi Khochbin Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers EMBO Molecular Medicine 5

Version of Record online: 4 JUL 2013 | DOI: 10.1002/emmm.201202034

Thumbnail image of graphical abstract

The nuclear factor CYCLON is a new MYC cooperating factor that drives tumor growth and Rituximab resistance in lymphoma. This resistance mechanism can be targeted by next-generation epigenetic therapy by BET bromodomain inhibition downstream of MYC.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field